Sacral neuromodulation (SNM) has reported clinical benefits across several bladder and bowel dysfunctions, including urinary incontinence, non-obstructive urinary retention, chronic pelvic pain, and fecal incontinence. Reported outcomes include at least a 50% reduction in daily urinary incontinence episodes in approximately 70% of patients, an average reduction of about 100 mL in post-void residual urine volume in reported urinary retention research, and improved bowel control.
A key part of SNM treatment is its staged evaluation process. Patients generally undergo approximately two weeks of test stimulation, and those achieving at least 50% symptom improvement may be considered for permanent implantation. Individual outcomes depend on the underlying condition, patient characteristics, and response to sacral neuromodulation treatment.
1. Clinical Outcomes of Sacral Neuromodulation Across Different Conditions
SNM is used to address selected bladder and bowel dysfunctions. The clinical outcomes reported on this website cover four main areas:
| Clinical condition | Reported treatment outcome |
|---|---|
| Urinary incontinence | Approximately 70% of patients experience at least a 50% reduction in daily incontinence episodes |
| Non-obstructive urinary retention | Reported research shows an average reduction of approximately 100 mL in post-void residual urine volume; some patients no longer require intermittent catheterization |
| Chronic pelvic pain | Average visual analogue scale (VAS) pain score decreases by approximately 4 points after six months of stimulation, using a 10-point scale |
| Neurogenic fecal incontinence | Approximately 60% of patients experience a reduction of more than 50% in incontinence days |
These figures are reported clinical outcomes, not guaranteed results for individual patients. They should also be interpreted according to the underlying study populations and evaluation methods. Patients may experience different responses depending on their diagnosis and clinical circumstances.
2. How Sacral Neuromodulation Treatment Response Is Evaluated
SNM follows a staged treatment approach to assess whether stimulation produces meaningful symptom improvement before permanent implantation.
Temporary test stimulation
Patients generally undergo an initial SNM test stimulation period of approximately two weeks. During this stage, changes in the relevant urinary or bowel symptoms are monitored.
Assessment of symptom improvement
A reduction of at least 50% in the relevant symptoms is used as the threshold for considering permanent implantation.
Permanent implantation decision
Patients who meet the response threshold may proceed to permanent implantation following clinical evaluation. Patients who do not achieve sufficient improvement require further assessment rather than automatic progression to permanent treatment.
This staged process allows the treatment response to be evaluated before a permanent implant is considered.
3. When Can Patients Expect to Notice Improvement?
The reported time to initial improvement varies according to the condition being treated.
| Symptom or condition | Reported observation period |
|---|---|
| Urinary leakage | Initial improvement may appear within 3–7 days |
| Chronic pelvic pain | Initial improvement may appear within 3–7 days |
| Urinary retention and bladder emptying | Improvement may require 1–2 weeks |
| Bowel dysfunction | Improvement may require approximately 2–4 weeks |
These periods are reported observation ranges rather than fixed recovery deadlines. Treatment response should be assessed according to individual symptoms and clinical findings.
4. Factors Influencing Sacral Neuromodulation Treatment Outcomes
Not every patient achieves the same response to sacral neuromodulation. Several clinical factors affect patient selection and outcome assessment.
- Underlying diagnosis: Urinary incontinence, non-obstructive urinary retention, pelvic pain, and bowel dysfunction have different treatment objectives and outcome measures.
- Baseline symptom severity: Initial symptom frequency and severity provide the reference point for measuring improvement.
- Neurological condition: The underlying cause of bladder or bowel dysfunction is important when assessing treatment suitability.
- Previous treatment history: Previous interventions and their results form part of the clinical assessment.
- Response to test stimulation: Improvement during temporary stimulation is an important factor in deciding whether permanent implantation should be considered.
Patient selection must follow condition-specific clinical evaluation. SNM should not be assumed suitable for every patient with neurogenic bladder. In particular, the AUA/SUFU guideline does not recommend SNM for patients with neurogenic lower urinary tract dysfunction associated with spinal cord injury or spina bifida.
5. Long-Term Outcomes and Follow-Up
The website reports that most patients who respond to SNM can maintain long-term benefits. However, continued assessment is important because treatment effectiveness may change over time.
If symptom improvement decreases, device programming adjustments may be considered to optimize stimulation settings.
Long-term management may include:
- Reviewing changes in urinary or bowel symptoms.
- Assessing whether initial treatment benefits are maintained.
- Adjusting stimulation parameters when clinically appropriate.
- Arranging follow-up evaluations and ongoing patient support.
For international patients, access to follow-up and device programming is an important consideration when planning treatment.
6. SNM Clinical Assessment and International Patient Support
Our medical team provides sacral neuromodulation treatment assessment and support for international patients. The evaluation considers medical history, previous treatment, imaging examinations, and urodynamic findings where available.
Our support includes:
- Medical record review: Reviewing medical histories, imaging examinations, urodynamic results, and previous treatment records.
- Remote preliminary assessment: Providing an initial evaluation of potential treatment suitability before travel.
- Second medical opinions: Providing written remote assessments, generally within 1–3 working days.
- Multidisciplinary evaluation: Involving relevant urology, neurourology, and rehabilitation professionals when appropriate.
- Post-treatment follow-up: Providing continued communication, remote device programming support, and follow-up arrangements for patients returning overseas.
Our medical team includes a physician with more than 30 years of urological clinical experience. The team has performed more than 1,000 SNM procedures, providing relevant clinical experience for patient assessment and treatment planning.
7. Request an Individual SNM Treatment Assessment
Clinical outcome figures provide useful reference points, but treatment suitability must be evaluated individually.
If you are considering sacral neuromodulation, send us your existing medical records, urodynamic reports, examination results, or previous treatment summaries.
Our medical team can review the available information and provide an initial assessment of your condition, potential treatment suitability, and the next steps for further evaluation.
Contact Our Medical Team
Hot Tags: clinical outcomes of sacral neuromodulation, China, price, pricelist, quotation, cost, Bladder stimulator, Decrease in pelvic pain severity, Decrease in urine leakage, Percutaneous sacral electrode implantation under LA, sacral neuromodulation, sacral stimulation system

